

**Supplemental Table 1.** Comparison of baseline characteristics between euthyroid patients without thyroid hormone medication (reference), euthyroid patients on thyroid hormone medication, and hypothyroid patients.\*

	EUTHYROID WITHOUT MEDICATION (n=2042)	EUTHYROID ON MEDICATION (n=323) p-value	HYPOTHYROID (n=350) p-value
TSH (mIU/L) Median [p25, p75] (Min-Max)	1.79 [1.17, 2.62] (0.40-5.14)	2.20 [1.27, 3.17] (0.40-5.21) N/A	7.65 [6.06, 12.28] (5.03-519.7) N/A
Age (years)	62.4 ± 15.8	67.2 ± 14.5 p<0.001	64.7 ± 14.3 p=0.01
Female sex	41.3%	60.4% p<0.001	46.3% p=0.08
Nonwhite race	40.4%	23.2% p<0.001	29.1% p<0.001
Diabetes‡	55.0%	63.5% p=0.004	57.1% p=0.4
Hosp for non-CV indication in preceding year‡	41.2%	46.8% p=0.06	42.9% p=0.6
Hypertension‡	84.5%	88.5% p=0.06	77.4% p=0.001
Hyperlipidemia‡	64.7%	74.9% p<0.001	62.6% p=0.4
Cerebrovascular disease‡	31.9%	36.5% p=0.1	34.3% p=0.4
Coronary artery disease‡	63.6%	69.0% p=0.06	70.0% p=0.02
Congestive heart failure‡	63.7%	70.0% p=0.03	76.3% p<0.001
Hosp for CV indication in preceding year‡	12.1%	16.7% p=0.02	17.7% p=0.004
Baseline use of exogenous thyroid hormone	0.0%	100.0% p<0.001	41.7% p<0.001
Date of ESRD diagnostic code			
2005	16.6%	12.4%	17.7%
2006	23.5%	22.9%	21.4%
2007	20.2%	21.1%	20.3%
2008	16.6%	18.6%	14.0%
2009	14.3%	16.1%	14.6%
2010	8.2%	8.4%	11.1%
2011	0.6%	0.6% p=0.6	0.9% p=0.5

\*Exposure group categorizations: Euthyroid without medication (referent group; TSH within reference range without

exogenous thyroid hormone), euthyroid on medication (TSH within reference range while on exogenous thyroid hormone),

and hypothyroid (TSH>ULN with or without exogenous thyroid hormone). Data presented as mean +/- SD or % except

where indicated. Significance testing compared to euthyroid patients without medication by 2-sample t-tests or chi-squared tests.

‡ Ascertained using ICD-9 diagnostic codes.

TSH, thyrotropin; CV, cardiovascular; Hosp, hospitalization; ESRD, end-stage renal disease

**Supplemental Table 2.** Comparison of baseline characteristics between euthyroid (reference), subclinical hypothyroid, and overt hypothyroid patients.\*

	EUTHYROID (n=2365)	SUBCLINICAL HYPOTHYROID (n=238)	OVERT HYPOTHYROID (n=112)
TSH (mIU/L) Median [p25, p75] (Min-Max)	1.83 [1.19, 2.69] (0.40-5.21)	6.39 [5.77, 7.85] (5.03-10.0) N/A	16.6 [12.6, 30.8] (10.1- 519) N/A
Age (years)	63.1 ± 15.7	63.7 ± 14.3 p=0.6	66.8 ± 14.0 p=0.02
Female sex	43.9%	45.4% p=0.7	48.2% p=0.4
Nonwhite race	38.0%	29.4% p=0.009	28.6% p=0.04
Diabetes‡	56.1%	57.1% p=0.8	57.1% p=0.8
Hosp for non-CV indication in preceding year‡	42.0%	37.0% p=0.1	55.4% p=0.005
Hypertension‡	85.1%	76.5% p=0.001	79.5% p=0.1
Hyperlipidemia‡	66.1%	61.3% p=0.1	65.2% p=0.8
Cerebrovascular disease‡	32.5%	31.9% p=0.9	39.3% p=0.1
Coronary artery disease‡	64.3%	72.3% p=0.0	65.2% p=0.9
Congestive heart failure‡	64.5%	75.2% p=0.001	78.6% p=0.002
Hosp for CV indication in preceding year‡	12.7%	16.8% p=0.08	19.6% p=0.03
Baseline use of exogenous thyroid hormone	13.7%	31.1% p<0.001	64.3% p<0.001
Date of ESRD diagnostic code			
2005	16.0%	18.1%	17.0%
2006	23.4%	22.3%	19.6%
2007	20.3%	19.8%	21.4%
2008	16.9%	13.0%	16.1%
2009	14.5%	14.3%	15.2%
2010	8.3%	11.3%	10.7%
2011	0.6%	1.3% p=0.4	0.00% p=0.9

\*Thyroid functional status categorizations: Euthyroid (referent group; TSH within reference range), subclinical hypothyroid

(TSH ULN-10mIU/L), and overt hypothyroid (TSH >10mIU/L). Data presented as mean +/- SD or % except where

indicated. Significance testing compared to euthyroid patients by 2-sample t-tests or chi-squared tests.

‡ Ascertained using ICD-9 diagnostic codes.

TSH, thyrotropin; CV, cardiovascular; Hosp, hospitalization; ESRD, end-stage renal disease